Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.0K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

80.7K
Overview
80.7K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

14.2K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.2K
T Cell Types and Functions01:24

T Cell Types and Functions

1.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BET inhibition synergizes with RLR signaling to enhance tumor immunogenicity and T cell recognition.

Cancer immunology research·2026
Same author

Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8<sup><b>+</b></sup> T cells.

Oncoimmunology·2026
Same author

Epigenetic remodeling in sarcoma promotes T-cell infiltration via modulation of the Hippo pathway.

Journal for immunotherapy of cancer·2026
Same author

Memory programming and new manufacturing paradigms in CAR-T cell therapy.

Cancer gene therapy·2026
Same author

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1.

Cell reports. Medicine·2025
Same author

Evaluating functional anti-tumor T cell responses in autologous 2D co-cultures using flow cytometry.

Methods in cell biology·2025

Related Experiment Video

Updated: Dec 1, 2025

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.1K

Counteracting CAR T cell dysfunction.

Mansour Poorebrahim1,2, Jeroen Melief3, Yago Pico de Coaña3

  • 1Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. mansour.poorebrahim@dkfz-heidelberg.de.

Oncogene
|November 10, 2020
PubMed
Summary

Strategies to prevent chimeric antigen receptor (CAR) T cell exhaustion and senescence can improve anti-tumor functions and persistence. This review explores pathways to enhance CAR T cell therapies by overcoming these challenges.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.6K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.2K

Related Experiment Videos

Last Updated: Dec 1, 2025

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.1K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.6K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.2K

Area of Science:

  • Immunology
  • Cell Biology
  • Cancer Therapy

Background:

  • Chimeric antigen receptor (CAR) T cell therapy shows promise but is limited by T cell dysfunction.
  • CAR T cell exhaustion and senescence are key barriers to sustained anti-tumor activity.
  • The tumor microenvironment (TME) and antigen load contribute to CAR T cell dysfunction.

Purpose of the Study:

  • To review strategies for blocking CAR T cell exhaustion and senescence.
  • To explore the potential of these strategies for enhancing adoptive cell transfer (ACT) therapies.
  • To discuss factors influencing CAR T cell efficacy and safety.

Main Methods:

  • Review of recent literature on CAR T cell exhaustion and senescence.
  • Focus on exhaustion-inducing pathways and their blockade.
  • Analysis of costimulation, cytokine exposure, and TME modulation effects.

Main Results:

  • Modified CAR T cells with "exhaustion-resistant" phenotypes demonstrate improved anti-tumor functions and longevity.
  • Senescence delay in CAR T cells is a feasible therapeutic approach.
  • Understanding exhaustion pathways offers potential for boosting ACT efficacy.

Conclusions:

  • Overcoming CAR T cell exhaustion and senescence is crucial for improving therapy outcomes.
  • Modulating costimulation, cytokines, and the TME can enhance CAR T cell efficacy and persistence.
  • Potential safety concerns associated with reinvigorated CAR T cells require careful consideration.